|
|
News Breaks | | | | January 13, 2013 | | 16:17 EDT |  | ABT | AbbVie issues second Synthroid recall, WSJ says
Abbott Laboratories' (ABT) former pharmaceutical unit, now known as AbbVie (ABBV) after being spun-off, recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, says the Wall Street Journal, adding that this is the second recall of the drug in six months. Reference Link | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 22, 2013 | | 07:28 EDT |  | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 08:03 EDT |  | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | |
|
|
|
|
|
|
